News & Research - HBM Partners AG

NEWS & RESEARCH

Portfolio News

HBM in the News

Industry Reports

Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (19 KB)
7.10.2019
Download
Swixx signs deal to represent Alexion in Russia & announces opening of Russian operations and Swixx appointed distributor for Alexion Russia (136 KB)
1.10.2019
Download
Adrenomed completes full enrollment with 300 patients in AdrenOSS-2 trial with Adrecizumab in septic shock (123 KB)
26.9.2019
Download
U.S. FDA accepts for review Viela Bio's first BLA filing (108 KB)
27.8.2019
Download
Harmony Biosciences Announces FDA Approval of WAKIX (pitolisant), a First-In-Class Medication for the Treatment of Excessive Daytime Sleepiness in Adult Patients with Narcolepsy (127 KB)
15.8.2019
Download
SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma (136 KB)
27.6.2019
Download
1mg to accelerate investments in Growth, Supply Chain & AI/ML driven personalized care (180 KB)
27.6.2019
Download
Viela Bio Closes $75 Million Series B Financing (108 KB)
17.6.2019
Download
Corvidia Therapeutics Initiates Phase 2b Dose-Finding Study for Ziltivekimab (207 KB)
13.6.2019
Download
SpringWorks Therapeutics Announces FDA Fast Track Designation for PD-0325901 for the Treatment of a Severe Form of Neurofibromatosis Type 1 (135 KB)
3.6.2019
Download

<2 3 456 7 >

Andreas Wicki, CEO HBM Healthcare Investments AG “The importance of biotech as the backbone of innovation of the pharma industry is growing all the time.” (156 KB)
18.08.2020
Download Read more
«Bedeutung von Biotech als Innovations-Rückgrat der Pharma-Industrie nimmt stetig zu» (196 KB)
18.08.2020
Download Read more
Biotech im Hoch: Nicht alle Healthcare-Unternehmen kommen gleich durch die Corona-Krise (499 KB)
25.07.2020
Download Read more
Virus eröffnet Anlage-Chancen (100 KB)
2.4.2020
Download Read more
Pharmaprofis kaufen keine Corona-Aktien (123 KB)
1.4.2020
Download Read more
Der Bedarf der Pharmakonzerne nach neuen Medikamenten ist ungestillt - Interview Dr. Andreas Wicki (302 KB)
6.11.2019
Download Read more
Investing in biotechnology - a lucrative approach (304 KB)
1.9.2019
Download Read more
Investieren in die Biotechnologie – ein aktiver Ansatz zahlt sich aus (4594 KB)
1.9.2019
Download Read more
Interview with Andreas Wicki (351 KB)
Download Read more
Interview with Ivo Staijen (263 KB)
17.7.2019
Download Read more
Biotech-Unternehmen schwimmen im Geld (309 KB)
25.5.2019
Download Read more
„Ungebremste Innovationskraft" (628 KB)
1.5.2019
Download Read more
Unbridled Capacity for Innovation (101 KB)
1.5.2019
Download Read more
Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)
23.1.2019
Download Read more
Investing in listed private equity – more than just an alternative (197 KB)
23.1.2019
Download Read more
Kleine Hersteller, grosses Potenzial (1007 KB)
1.1.2019
Download Read more
Investieren in den Gesundheitssektor – Chancen für den Anleger (487 KB)
4.11.2018
Download Read more
A Biotechnology Bonanza (397 KB)
1.10.2018
Download Read more
Andreas Wicki, CEO HBM Healthcare Investments, im Interview (345 KB)
13.8.18
Download Read more
Die Reize der Swiss Biotechs (581 KB)
25.7.2018
Download Read more

Trends in New Drug Approvals

Report covers new drugs approved by US FDA. The latest report as well as a list of new drug approvals since 2003 are available for download.

Analysis of FDA Approvals 2018 and Previous Years (1147 KB)
Download
FDA Approved NMEs 2003-2018 (86 KB)
Download

HBM Pharma/Biotech M&A Report

HBM Partners carries out an ongoing analysis of all trade sales of public and private US and European biotech and pharma companies. The latest HBM Pharma/Biotech M&A Report as well as information on M&A transactions since 2005 are available for download:

Credits

Sitemap

Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (19 KB)

Swixx signs deal to represent Alexion in Russia & announces opening of Russian operations and Swixx appointed distributor for Alexion Russia (136 KB)

Adrenomed completes full enrollment with 300 patients in AdrenOSS-2 trial with Adrecizumab in septic shock (123 KB)

U.S. FDA accepts for review Viela Bio's first BLA filing (108 KB)

Harmony Biosciences Announces FDA Approval of WAKIX (pitolisant), a First-In-Class Medication for the Treatment of Excessive Daytime Sleepiness in Adult Patients with Narcolepsy (127 KB)

SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma (136 KB)

1mg to accelerate investments in Growth, Supply Chain & AI/ML driven personalized care (180 KB)

Viela Bio Closes $75 Million Series B Financing (108 KB)

Corvidia Therapeutics Initiates Phase 2b Dose-Finding Study for Ziltivekimab (207 KB)

SpringWorks Therapeutics Announces FDA Fast Track Designation for PD-0325901 for the Treatment of a Severe Form of Neurofibromatosis Type 1 (135 KB)

Andreas Wicki, CEO HBM Healthcare Investments AG “The importance of biotech as the backbone of innovation of the pharma industry is growing all the time.” (156 KB)

«Bedeutung von Biotech als Innovations-Rückgrat der Pharma-Industrie nimmt stetig zu» (196 KB)

Biotech im Hoch: Nicht alle Healthcare-Unternehmen kommen gleich durch die Corona-Krise (499 KB)

Virus eröffnet Anlage-Chancen (100 KB)

Pharmaprofis kaufen keine Corona-Aktien (123 KB)

Der Bedarf der Pharmakonzerne nach neuen Medikamenten ist ungestillt - Interview Dr. Andreas Wicki (302 KB)

Investing in biotechnology - a lucrative approach (304 KB)

Investieren in die Biotechnologie – ein aktiver Ansatz zahlt sich aus (4594 KB)

Interview with Andreas Wicki (351 KB)

Interview with Ivo Staijen (263 KB)

Biotech-Unternehmen schwimmen im Geld (309 KB)

„Ungebremste Innovationskraft" (628 KB)

Unbridled Capacity for Innovation (101 KB)

Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)

Investing in listed private equity – more than just an alternative (197 KB)

Kleine Hersteller, grosses Potenzial (1007 KB)

Investieren in den Gesundheitssektor – Chancen für den Anleger (487 KB)

A Biotechnology Bonanza (397 KB)

Andreas Wicki, CEO HBM Healthcare Investments, im Interview (345 KB)

Die Reize der Swiss Biotechs (581 KB)

Trends in New Drug Approvals

Analysis of FDA Approvals 2018 and Previous Years (1147 KB)

FDA Approved NMEs 2003-2018 (86 KB)

HBM Pharma/Biotech M&A Report

Biopharma M&A Update H1 2019 and Potential Implications of Mega Mergers for Smaller Biopharma Deal Making (470 KB)

HBM Pharma / Biotech M&A Report 2020 (1299 KB)

Pharma / Biotech M&A Transctions 2005-2019 (119 KB)